StockRing.com   Home    DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH   
  iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   
 10/31/2014, (NASDAQ:SLXP), $145.2 +0.70, +0.48%, "SELL" Salix Pharmaceuti Stock
 




  
  

SLXP rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

On   10/31/2014   StockRing.com recommends to   "SELL"   SLXP   stock at current price of   $145.2.
Today SLXP stock opened at $147.14 and was trading in the daily range of $ 143.56 - 147.5124 per share.
Salix Pharmaceuti (NASDAQ:SLXP) Market capitalization is $9.247B. SLXP average daily volume is 1,853,950.
On last trading session SLXP stock traded 606,780 shares. Also the Short Ratio for (NASDAQ:SLXP) stock is 3.40.
Last year Salix Pharmaceuti(NASDAQ:SLXP) before taxes (EBITDA) (ttm) earned $454.5M on revenue of $1.262B.
SLXP 50-Day Moving Average is $148.06 vs. $145.2 now and 200-Day Moving Average is $131.6 vs. $145.2.
--------------------------------------------------------------------------------------------------------------------
VIX is "HOLD".  Nasdaq is "HOLD".  S&P 500 is "HOLD" on  5/16/2014
--------------------------------------------------------------------------------------------------------------------
SLXP Earnings Per Share - EPS (ttm) is 0.9. SLXP Stock Price Per Earnings ratio - P/E is 160.02.
Salix Pharmaceuti(NASDAQ:SLXP) stock pays a dividend of $0.00 per share which is a yield of N/A%.
On average analysts predict that One Year Target Estimated price for SLXP stock is $167.53.
In the last 52 weeks SLXP stock was trading in the range of $70.64 - 172.98.
 
 
  Our FREE iPhone App Buy-Sell-Hold ratings for 4568 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 5/16/2014 6:13:26 PM
2. DOW30+    Part 2    192 Stocks    Updated: 5/16/2014 6:18:11 PM
3. DOW30+    Part 3    193 Stocks    Updated: 5/16/2014 6:23:19 PM
4. DOW30+    Part 4    195 Stocks    Updated: 5/16/2014 6:27:30 PM
 
5. ENERGY    Part 1    188 Stocks    Updated: 5/30/2014 10:49:50 AM
6. ENERGY    Part 2    186 Stocks    Updated: 5/30/2014 10:45:38 AM
7. ENERGY    Part 3    196 Stocks    Updated: 5/30/2014 10:40:22 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 5/19/2014 11:03:20 PM
9. HEALTH    Part 2    138 Stocks    Updated: 5/19/2014 11:06:54 PM
 
10. FINANCE    Part 1    191 Stocks    Updated: 5/29/2014 9:02:46 AM
11. FINANCE    Part 2    190 Stocks    Updated: 5/29/2014 9:08:02 AM
12. FINANCE    Part 3    188 Stocks    Updated: 5/29/2014 9:13:08 AM
13. FINANCE    Part 4    188 Stocks    Updated: 5/29/2014 9:17:57 AM
14. FINANCE    Part 5    190 Stocks    Updated: 5/29/2014 9:22:59 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 5/22/2014 12:09:15 AM
16. SERVICE    Part 2    185 Stocks    Updated: 5/22/2014 12:10:17 AM
17. SERVICE    Part 3    183 Stocks    Updated: 5/22/2014 12:02:57 AM
18. SERVICE    Part 4    193 Stocks    Updated: 5/22/2014 12:07:53 AM
 
19. TECH    Part 1    187 Stocks    Updated: 5/20/2014 10:04:33 AM
20. TECH    Part 2    183 Stocks    Updated: 5/20/2014 10:10:24 AM
21. TECH    Part 3    184 Stocks    Updated: 5/20/2014 10:15:47 AM
22. TECH    Part 4    102 Stocks    Updated: 5/20/2014 10:27:15 AM
 
23. IPOs    200 Stocks    Updated:  TODAY , 6/10/2014 3:37:13 AM
 
24. ETFs    Part 1    193 Stocks    Updated: 5/16/2014 6:48:58 PM
25. ETFs    Part 2    191 Stocks    Updated: 5/16/2014 6:52:54 PM
26. ETFs    Part 3    157 Stocks    Updated: 5/16/2014 6:56:31 PM

BUY  DOW 30+: FF  FTK  PTEN  NR  EXH     ENERGY: ADMA  RNG  CDW  CBA  BLUE     HEALTH: ACWX  EPHE  FM  DVYA  AOM 
      FINANCE: XLK  DWX  BWZ  GII  SCPB     SERVICES: UST  MLPX  BRAQ  YCL  EMFM     TECH: CSGP  WDC  ONNN  RENN  JNPR 
SELL  DOW 30+: PVA  PWE  FOE  GNE  EOX     ENERGY: RMAX  SEAS  NBCB  PETX  VOYA     HEALTH: ITA  ICLN  EIRL  SCZ  PICK 
      FINANCE: XME  XSW  KBE  EWO  BAL     SERVICES: VIXM  EEV  UVXY  QID  AGQ     TECH: BRKR  CPHD  IPGP  LLTC  MDRX 


Samples of StockRing Real Time "Buy-Sell-Hold" stock Ratings:



  Enter Stock:  
  
    
    
 
 



Download StockRing Free  Buy-Sell-Hold iPhone
App for 1,200 stocks in Energy Healthcare Finance Services & Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH

  Our FREE iPhone App Buy-Sell-Hold ratings for 4568 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 5/16/2014 6:13:26 PM
2. DOW30+    Part 2    192 Stocks    Updated: 5/16/2014 6:18:11 PM
3. DOW30+    Part 3    193 Stocks    Updated: 5/16/2014 6:23:19 PM
4. DOW30+    Part 4    195 Stocks    Updated: 5/16/2014 6:27:30 PM
 
5. ENERGY    Part 1    188 Stocks    Updated: 5/30/2014 10:49:50 AM
6. ENERGY    Part 2    186 Stocks    Updated: 5/30/2014 10:45:38 AM
7. ENERGY    Part 3    196 Stocks    Updated: 5/30/2014 10:40:22 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 5/19/2014 11:03:20 PM
9. HEALTH    Part 2    138 Stocks    Updated: 5/19/2014 11:06:54 PM
 
10. FINANCE    Part 1    191 Stocks    Updated: 5/29/2014 9:02:46 AM
11. FINANCE    Part 2    190 Stocks    Updated: 5/29/2014 9:08:02 AM
12. FINANCE    Part 3    188 Stocks    Updated: 5/29/2014 9:13:08 AM
13. FINANCE    Part 4    188 Stocks    Updated: 5/29/2014 9:17:57 AM
14. FINANCE    Part 5    190 Stocks    Updated: 5/29/2014 9:22:59 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 5/22/2014 12:09:15 AM
16. SERVICE    Part 2    185 Stocks    Updated: 5/22/2014 12:10:17 AM
17. SERVICE    Part 3    183 Stocks    Updated: 5/22/2014 12:02:57 AM
18. SERVICE    Part 4    193 Stocks    Updated: 5/22/2014 12:07:53 AM
 
19. TECH    Part 1    187 Stocks    Updated: 5/20/2014 10:04:33 AM
20. TECH    Part 2    183 Stocks    Updated: 5/20/2014 10:10:24 AM
21. TECH    Part 3    184 Stocks    Updated: 5/20/2014 10:15:47 AM
22. TECH    Part 4    102 Stocks    Updated: 5/20/2014 10:27:15 AM
 
23. IPOs    200 Stocks    Updated:  TODAY , 6/10/2014 3:37:13 AM
 
24. ETFs    Part 1    193 Stocks    Updated: 5/16/2014 6:48:58 PM
25. ETFs    Part 2    191 Stocks    Updated: 5/16/2014 6:52:54 PM
26. ETFs    Part 3    157 Stocks    Updated: 5/16/2014 6:56:31 PM

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

Our FREE iPhone App with Buy-Sell-Hold ratings for 4,030 stocks:

  iPhone App Buy-Sell-Hold Ratings for 5-5-2013
           
           
           
           
     
  

 
  Enter Stock:  
  
    
    
 



10/31/2014  Friday, October 31, 2014 (Irvine, California) Today StockRing.com Recommendation is to "SELL"for Salix Pharmaceuti (NASDAQ:SLXP) Stock. SLXP stock opening price was $147.14 per share. Current price of NASDAQ:SLXP Stock is $145.2 per share and it is $+0.70, (+0.48%) today and it was trading in the daily range of $143.56 - 147.5124 per share. Current Bid Price for (NASDAQ:SLXP) stock is $145.11 and the Ask Price is $145.22. In the last 52 weeks SLXP stock was trading in the range of $70.64 - 172.98. 50-Day Moving Average for (NASDAQ:SLXP) stock is $148.06 and 200-Day Moving Average is $131.6. On average analysts predict that One Year Target Estimated price for (NASDAQ:SLXP) stock is $167.53.

Salix Pharmaceuti (NASDAQ:SLXP) is rated as a sell on 9/10/2014 1:26:20 AM.

Salix Pharmaceuti (NASDAQ:SLXP) Market capitalization is $9.247B. (NASDAQ:SLXP) stock average daily volume is 1,853,950 shares per day. However, on last trading session of 12:00pm, 2012 SLXP stock traded 606,780 shares. Also The Number of days it would take short sellers on average to repurchase all the borrowed shares or Short Ratio for (NASDAQ:SLXP) stock is 3.40. On previous trading session SLXP Stock closed at $144.50 per share.

Last year Salix Pharmaceuti (NASDAQ:SLXP) before taxes (EBITDA) (ttm) earned $454.5M on total revenue of $1.262B. Earnings Per Share - EPS (ttm) for SLXP stock is 0.9. Also, (NASDAQ:SLXP) Stock Price Per Earnings ratio - P/E is 160.02. Thus, (NASDAQ:SLXP) Stock Price/Sales (ttm) ratio is 7.29 and Price/Book (mrq) ratio is 12.46.

(NASDAQ:SLXP) Stock does NOT PAY any dividend. So at this time (NASDAQ:SLXP) Stock maintains Trailing Annual Dividend Rate at 0.00 .


StockRing Recommendations for Salix Pharmaceuti (NASDAQ:SLXP) Stock are updated daily here

http://StockRing.com/sr/Buy-Sell-Hold-Stock-Analysis-Ratings.asp?StockName=SLXP

At this time StockRing recommends to buy LONG positions on many stocks from Dow 30+ stocks that currently have a BUY or SUPER BUY rating. If you decide to take a SHORT position and actually sell some stocks sjort right now - please check the section of Dow 30+ stocks that have a SELL or SUPER SELL rating.

If you would like to receive Buy-Sell-Hold ratings for stocks from Energy, Healthcare, Finance, Services & Hi-Tech sectors on your iPhone, then please download Buy-Sell-Hold iPhone App here:


Free Limited or $10 Full Version  Buy-Sell-Hold iPhone App
for 1,200 stocks in Energy, Healthcare, Finance, Services and Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH


 
  Enter Stock:  
  
    
    
 
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

NASDAQ:SLXP Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info

SLXP rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

10/31/2014 1 Year Stock market price chart for Salix Pharmaceuti (NASDAQ:SLXP) Stock on Friday, October 31, 2014
  
1 Year SLXP 1 Year Dow Jones
1 Year Nasdaq 1 Year S&P 500
10/31/2014 5 days Stock market price chart for Salix Pharmaceuti (NASDAQ:SLXP) Stock on Friday, October 31, 2014
  
5 Days SLXP 5 Days Dow Jones
5 Days Nasdaq 5 Days S&P 500
  

EUROs for $1 DOLLAR: 30 days
     

NASDAQ:SLXP Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

SLXP rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

10/31/2014 Stock market price quote data for Salix Pharmaceuti (NASDAQ:SLXP) Stock on Friday, October 31, 2014

Last Trade: 145.2
Trade Time: 12:00pm
Change: +0.70, (+0.48%)
Prev Close: 144.50
Open: 147.14
Bid: 145.11
Ask: 145.22
1y Target Est: $167.53
50-Day Moving Average: 148.06
200-Day Moving Average:
131.6
Short Ratio: 3.40
Trailing Annual Dividend Rate: 0.00
Day's Range: 143.56 - 147.5124
52wk Range: 70.64 - 172.98
Volume: 606,780
Avg Vol: 1,853,950
Market Cap: 9.247B
P/E (ttm): 160.02
EPS (ttm): 0.9
Div & Yield: 0.00 (N/A%)
Revenue (ttm): 1.262B
Earnings before Tax (EBITDA) (ttm): 454.5M
Price/Sales (ttm): 7.29
Price/Book (mrq): 12.46
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

  
  
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

SLXP rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs



10/31/2014 Latest stock market news data for Salix Pharmaceuti (NASDAQ:SLXP) Stock on Friday, October 31, 2014

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

SLXP rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

Why Salix Pharmaceuticals (SLXP) Stock Is Surging Today
TheStreet.com - Oct 3, 2014
NEW YORK (TheStreet) -- Shares of Salix Pharmaceuticals Ltd. (SLXP) are up 3.71% to $156.70 in pre-market trade after it was reported that the company is in talks to sell itself to Actavis Plc, (ACT) , sources told Bloomberg, after it failed to reach a ...
Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) to Ring The Nasdaq Stock Market ... - GlobeNewswire (press release)
Salix Pharma scuttles Cosmo Technologies merger - U.S. News & World Report
RSI Alert: Salix Pharmaceuticals (SLXP) Now Oversold
Forbes - Oct 13, 2014
In trading on Monday, shares of Salix Pharmaceuticals Ltd (NASD: SLXP) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $135.60 per share.
Stifel Raises Price Target On Salix Pharmaceuticals, Ltd. On Possible Takeover
Benzinga - Oct 1, 2014
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) received a price target increase from $155 to $185 by Stifel, which maintained a Buy rating.
Salix Pharmaceuticals Price Target Raised to $185.00 (SLXP) - Ticker Report
Stifel Nicolaus Increases Salix Pharmaceuticals Price Target to $185.00 (SLXP) - Watch List News (press release)
Pharma Stocks in the News: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP ...
Street Newswire - Oct 8, 2014
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) said it has received final Food and Drug Administration approval for its Uceris rectal foam product to induce remission in patients with active mild-to-moderate distal ulcerative colitis.
A Bizarre Pharma Love Triangle
Seeking Alpha (registration) - Oct 1, 2014
Salix Pharmaceuticals is a specialty pharma company that specializes in gastroenterology treatments. In the article, I mentioned Salix Pharmaceuticals was being discussed as a prime candidate to do a tax-inversion deal. Just a few days later on July ...
Salix Said in Talks to Sell to Actavis as Allergan Fades - Bloomberg
Shareholder T. Rowe Price urges Allergan to hold off on deals - Reuters
Salix's Xifaxan Sales Expected To Go Downhill
Bidness ETC - Oct 8, 2014
Sales of Salix Pharmaceuticals, Ltd.'s (SLXP) drug Xifaxan face the risk of decline due to availability of new all-oral drugs for treatment of the hepatitis C virus (HCV), according to physician survey along with research conducted by Credit Suisse ...
Sell Side's Views On Salix-Actavis Potential Merger
Bidness ETC - Oct 7, 2014
Allergan, in a desperate attempt to fend off Valeant's bid, revived acquisition talks with another pharmaceutical company, Salix Pharmaceuticals, Ltd. (SLXP), in September. Allergan believes that acquisition of Salix would make Allergan a complex and ...
Salix: The Field of Potential Buyers is Vast, Analyst Says - Wall Street Journal (blog)
Exclusive: Actavis plans new merger approach for Allergan - sources - Reuters India
Salix Pharmaceuticals Announces 3Q2014 Financial Results Conference Call ...
MarketWatch - Oct 23, 2014
RALEIGH, N.C., Oct 23, 2014 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. SLXP, -1.73% today announced that the Company will report third quarter 2014 financial results following the close of the U.S.
Stocks in the News – Atmel, (NASDAQ:ATML), Salix Pharmaceuticals, (NASDAQ ... - Techsonian (press release)
Salix Pharmaceuticals Outlines Data Presentations at American College of ...
Rock Hill Herald (press release) - Oct 17, 2014
RALEIGH, N.C. - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to research of two of the Company's products are scheduled to take place during the American College of Gastroenterology (ACG) 2014 Annual ...
EC approves ulcerative colitis med
Seeking Alpha (registration) - Oct 22, 2014
The European Commission approves privately-held Switzerland-based Ferring Pharmaceuticals' Cortiment (budesonide) for the induction of remission in patients with active mild-to-moderate ulcerative colitis.
Ferring Pharmaceuticals: CORTIMENT ® MMX® , a new treatment for ulcerative ... - Business Wire (press release)

 
DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

SLXP rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs


10/31/2014 News from StockRing Blog about Salix Pharmaceuti (NASDAQ:SLXP) Stock on Friday, October 31, 2014



Copyright © 2014 StockRing.com. All rights reserved.
Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds   Form

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.